Histone H3.3-K27M Neoantigen Vaccine Therapy / TCRCure - LARVOL DELTA

ENACTING: Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Yang Zhang | Terminated ➔ Completed

Trial completion • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor

ENACTING: Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Yang Zhang | N=30 ➔ 16 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2024 ➔ Oct 2024; The interim analysis has demonstrated the safety of the treatment and indicated a moderate survival benefit for patients. Essentially, the primary objectives have been achieved.

Enrollment change • Trial primary completion date • Trial termination • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor

ENACTING: Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Yang Zhang | Trial completion date: Apr 2024 ➔ Dec 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor